BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

Beschikbaar vanaf:

NOVOCOL PHARMACEUTICAL OF CANADA INC

ATC-code:

N01BB51

INN (Algemene Internationale Benaming):

BUPIVACAINE, COMBINATIONS

Dosering:

5MG; 0.0091MG

farmaceutische vorm:

SOLUTION

Samenstelling:

BUPIVACAINE HYDROCHLORIDE 5MG; EPINEPHRINE BITARTRATE 0.0091MG

Toedieningsweg:

BLOCK/INFILTRATION

Eenheden in pakket:

1.8ML

Prescription-type:

Ethical

Therapeutisch gebied:

LOCAL ANESTHETICS

Product samenvatting:

Active ingredient group (AIG) number: 0231290002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2012-04-16

Productkenmerken

_Novocol Pharmaceutical of Canada, Inc._
Page 1 of 24
PRODUCT MONOGRAPH
BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION
(BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP)
_ _
_ _
_ _
_Local Anaesthetic for Dental Use _
Sponsor/Manufacturer:
Novocol Pharmaceutical of Canada, Inc.
25 Wolseley Court,
Cambridge, Ontario,
N1R 6X3
Date of Preparation:
March 15, 2012
Submission Control No: 153985
_Novocol Pharmaceutical of Canada, Inc._
Page 2 of 24
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................................3
SUMMARY PRODUCT INFORMATION
....................................................................................................3
INDICATIONS AND CLINICAL
USE..........................................................................................................3
CONTRAINDICATIONS
...............................................................................................................................4
WARNINGS AND
PRECAUTIONS..............................................................................................................4
ADVERSE REACTIONS
...............................................................................................................................7
DRUG
INTERACTIONS................................................................................................................................8
DOSAGE AND
ADMINISTRATION..........................................................................................................10
OVERDOSAGE
............................................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
........................................................................................13
STORAGE AND STABILITY
.....................................................................................................................15
SPECIAL HANDLING INSTRUCTIONS
...........